129 related articles for article (PubMed ID: 11705443)
1. Liver failure in a patient treated with long-term rosiglitazone therapy.
Gouda HE; Khan A; Schwartz J; Cohen RI
Am J Med; 2001 Nov; 111(7):584-5. PubMed ID: 11705443
[No Abstract] [Full Text] [Related]
2. Rosiglitazone-induced granulomatous hepatitis.
Dhawan M; Agrawal R; Ravi J; Gulati S; Silverman J; Nathan G; Raab S; Brodmerkel G
J Clin Gastroenterol; 2002; 34(5):582-4. PubMed ID: 11960075
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.
McMorran M; Vu D
CMAJ; 2001 Jul; 165(1):82-3, 86-7. PubMed ID: 11468963
[No Abstract] [Full Text] [Related]
4. Rosiglitazone toxicity.
Ravinuthala RS; Nori U
Ann Intern Med; 2000 Oct; 133(8):658. PubMed ID: 11033603
[No Abstract] [Full Text] [Related]
5. Rosiglitazone and hepatic failure.
Freid J; Everitt D; Boscia J
Ann Intern Med; 2000 Jan; 132(2):164. PubMed ID: 10644281
[No Abstract] [Full Text] [Related]
6. Correction: Liver injury and rosiglitazone.
Ann Intern Med; 2000 Aug; 133(3):237. PubMed ID: 10906846
[No Abstract] [Full Text] [Related]
7. Isolated elevation of alkaline phosphatase level associated with rosiglitazone.
Hachey DM; O'Neil MP; Force RW
Ann Intern Med; 2000 Nov; 133(9):752. PubMed ID: 11074926
[No Abstract] [Full Text] [Related]
8. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
10. Rosiglitazone maleate. Ketotifen fumarate.
Am J Health Syst Pharm; 1999 Oct; 56(19):1924-6. PubMed ID: 10554908
[No Abstract] [Full Text] [Related]
11. Lessons from the glitazones: a story of drug development.
Gale EA
Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
[TBL] [Abstract][Full Text] [Related]
12. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Lenhard MJ; Funk WB
Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222
[No Abstract] [Full Text] [Related]
13. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Al-Salman J; Arjomand H; Kemp DG; Mittal M
Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
[TBL] [Abstract][Full Text] [Related]
14. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.
Bonkovsky HL; Azar R; Bird S; Szabo G; Banner B
Dig Dis Sci; 2002 Jul; 47(7):1632-7. PubMed ID: 12141828
[TBL] [Abstract][Full Text] [Related]
15. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
16. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Lebovitz HE; Kreider M; Freed MI
Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone-associated hepatic failure.
Booth AM; Caldwell SH; Iezzoni JC
Am J Gastroenterol; 2000 Feb; 95(2):557-8. PubMed ID: 10685776
[No Abstract] [Full Text] [Related]
18. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.
Chan KA; Truman A; Gurwitz JH; Hurley JS; Martinson B; Platt R; Everhart JE; Moseley RH; Terrault N; Ackerson L; Selby JV
Arch Intern Med; 2003 Mar; 163(6):728-34. PubMed ID: 12639207
[TBL] [Abstract][Full Text] [Related]
19. [Severe electrolyte imbalance and edema in therapy with rosiglitazone].
Kuschel U; Hesselbarth N; Herrmann A; Hippius M; Hoffmann A
Med Klin (Munich); 2002 Sep; 97(9):553-5. PubMed ID: 12371084
[TBL] [Abstract][Full Text] [Related]
20. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.
Osei SY; Koro CE; Cobitz AR; Kolatkar NS; Stender M
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1244-6. PubMed ID: 19655316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
